Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2010 Oct 25.
Published in final edited form as: Braz J Med Biol Res. 2009 Jul 3;42(8):761–764. doi: 10.1590/s0100-879x2009005000008

High HTLV-1 proviral load, a marker for HTLV-1-associated myelopathy/tropical spastic paraparesis, is also detected in patients with infective dermatitis associated with HTLV-1

J Primo 1, I Siqueira 3, MCF Nascimento 3, MF Oliveira 1, L Farre 4, EM Carvalho 3, AL Bittencourt 2
PMCID: PMC2963476  NIHMSID: NIHMS241997  PMID: 19578703

Abstract

Salvador (BA, Brazil) is an endemic area for human T-cell lymphotrophic virus type 1 (HTLV-1). The overall prevalence of HTLV-1 infection in the general population has been estimated to be 1.76%. HTLV-1 carriers may develop a variety of diseases such as adult T-cell leukemia/lymphoma, HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and infective dermatitis associated with HTLV-1 (IDH). IDH is a chronic and severe form of childhood exudative and infective dermatitis involving mainly the scalp, neck and ears. It has recently been observed that 30% of patients with IDH develop juvenile HAM/TSP. The replication of HTLV-1 has been reported to be greater in adult HAM/TSP patients than in asymptomatic HTLV-1 carriers. In the current study, the proviral load of 28 children and adolescents with IDH not associated with HAM/TSP was determined and the results were compared to those obtained in 28 HTLV-1 adult carriers and 28 adult patients with HAM/TSP. The proviral load in IDH patients was similar to that of patients with HAM/TSP and much higher than that found in HTLV-1 carriers. The high levels of proviral load in IDH patients were not associated with age, duration of illness, duration of breast-feeding, or activity status of the skin disease. Since proviral load is associated with neurological disability, these data support the view that IDH patients are at high risk of developing HAM/TSP.

Keywords: Infective dermatitis associated with HTLV-1, HTLV-1-associated myelopathy/tropical spastic paraparesis, HTLV-1 proviral loads

Introduction

Salvador (BA, Brazil) is an endemic area for human T-cell lymphotrophic virus type 1 (HTLV-1). The overall prevalence of HTLV-1 infection in the general population has been estimated to be 1.76% (1). HTLV-1 carriers may develop a variety of diseases such as adult T-cell leukemia/lymphoma (ATL), HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and infective dermatitis associated with HTLV-1 (IDH). While IDH is a childhood disease, ATL and HAM/TSP are considered to be adult diseases. IDH is a chronic and severe form of exudative and infective childhood dermatitis involving mainly the scalp, neck and ears, and consisting of a generalized papular rash, nasal discharge and crusting of the nostrils. The disease responds immediately to antibiotic or sulfamethoxazole-trimethoprim therapy and, conversely, relapses immediately once treatment is withdrawn (2,3).

It has recently been observed that 30% of patients with IDH develop juvenile HAM/TSP (4) and this skin manifestation probably represents a risk factor for the development of ATL (5,6).

Maloney et al. (7) studied 28 asymptomatic infected children and observed an elevated viral load in only 2 of them, one of whom developed IDH. There is only 1 case of IDH in children in which HTLV-1 proviral load was determined. This case had a coinfection with Strongyloides stercoralis and presented a high proviral load. This same finding has been described in adult carriers with strongyloidiasis (8).

In a study evaluating seven carrier children with seborrheic dermatitis compared with 19 carrier children without seborrheic dermatitis, a higher mean proviral load [7.5 copies/100,000 peripheral blood mononuclear cells (PBMCs)] was found in children with seborrheic dermatitis compared to children without seborrheic dermatitis (3.1 copies/100,000 PBMCs) (9). Recently, it was reported that the proviral load in HTLV-1-infected children with a type of eczema not considered to be IDH increased to a median of 9220 copies/100,000 PBMCs at equilibrium, which was significantly higher than the median proviral load found in carrier children without eczema or in adult carriers (10).

In the current study, the proviral load of 28 children and adolescents with IDH not associated with HAM/TSP was determined and the results were compared to those obtained in 28 HTLV-1 adult carriers and 28 adult patients with HAM/TSP.

Material and Methods

The IDH patients were diagnosed and followed up at the Dermatology clinic and referred to the Neuropediatric clinic of Complexo Hospitalar Universitário Prof. Edgard Santos, Universidade Federal da Bahia. The HAM/TSP patients were being followed up at the HTLV-1 clinic of the same hospital. The HTLV-1 carriers were selected consecutively from blood bank donors. The group of IDH patients consisted of 18 girls and 10 boys, all of African descendent. Patient age ranged from 2 to 16 years (mean: 10.8 ± 3.6 years) at the time of blood sampling. Duration of breast-feeding ranged from 0.1 to 4.9 years (mean: 2 ± 1.3 years) and the duration of the disease ranged from 0.3 to 15 years (mean: 8.6 ± 3.9 years). Twenty-four patients (85.7%) had active disease at the time of blood sampling, while the remaining four (14.3%) were in remission. Neurological examination failed to reveal HAM/TSP in any of the 28 IDH patients. The presence of HTLV-1/II antibodies was investigated by ELISA and confirmed by Western blot (HTLV blot 2.4, Genelab, Singapore). All patients were HIV-negative. Stool examinations were performed in all patients at the time of blood sampling. The diagnosis of IDH was made according to established criteria (2,3). The DNA was extracted from 106 PBMCs using a phenol/chloroform procedure (11). HTLV-1 proviral load was determined using real-time TaqMan PCR (11). The GraphPad Prism 3.03 software (USA) was applied for statistical analysis and P values <0.05 were considered to be statistically significant. The Mann-Whitney U-test was used to compare data. The study was approved by the Ethics Committee of the Complexo Hospitalar Universitário Prof. Edgard Santos, Universidade Federal da Bahia, and the parents or legal guardians of the participants gave written informed consent at the time of blood sampling.

Results

The proviral loads of IDH patients were much higher (Figure 1), with a median of 160.480 (range: 26.382–965.825) copies per 106 PBMCs compared to the HTLV-1 adult carriers, who presented a median of 25.337 (range: 19.0–133.251) copies per 106 PBMCs (P < 0.0001). No statistically significant difference in proviral load was found between the IDH and the adult HAM/TSP patients. The proviral loads of adult HAM/TSP patients were also higher than those found in carriers, with a median of 127.055 (range: 35.0–691.862) copies per 106 PBMCs (P = 0.0017). No statistically significant associations were observed between proviral loads and age, duration of breast-feeding, duration of IDH and the status of disease activity (Table 1). Examination of stool specimens detected Strongyloides stercoralis in only 1 patient whose proviral load was 299.680 copies per 106 PBMCs.

Figure 1.

Figure 1

Proviral loads of IDH patients, HTLV-1 carriers and HAM/TSP patients. Proviral load was assessed in PBMCs from 28 IDH patients, 28 HTLV-1 carriers and 28 HAM/TSP patients. Proviral load was significantly higher in IDH patients compared to HTLV-1 carriers (P < 0.0001, Mann-Whitney U-test). IDH = infective dermatitis associated with HTLV-1; HTLV-1 = human T-cell lymphotrophic virus type 1; HAM/TSP = HTLV-1-associated myelopathy/tropical spastic paraparesis.

Table 1.

Proviral loads of infective dermatitis associated with human T-cell lymphotrophic virus type 1 (HTLV-1) patients.

No. of IDH cases Proviral load (median) Range
Age at the time of blood sampling
 ≤10 years 13 118.519 32.983–566.368
 >10 years 15 206.262 26.382–965.825
Duration of breast-feeding*
 ≤1.0 year 7 70.222 26.382–255.070
 >1.0 year 19 206.262 32.983–965.825
Duration of disease**
 ≤10 years 15 177.778 32.983–965.825
 >10 years 12 138.283 26.382–386.874
Status of activity of disease
 In activity 24 138.283 26.382–965.825
 In remission 4 245.914 85.259–428.166

IDH = infective dermatitis associated with HTLV-1.

*

No information was available about 2 patients: one was an orphan and the other was not breast-fed and was infected through blood transfusion.

**

This information was missing for the orphan patient. There were no statistical differences between subgroups for age, duration of breast feeding, duration of disease, or status of disease (Mann-Whitney U-test).

Discussion

Many studies have emphasized the importance of evaluating HTLV-1 proviral load in individuals at a higher risk for HAM/TSP (12). As previously shown, patients with IDH have a high risk of developing HAM/TSP (4,6). The replication of HTLV-1 has been reported to be greater in adult HAM/TSP patients than in asymptomatic HTLV-1 carriers (12). In the present study, proviral load was found to be higher in IDH patients than in HTLV-1 carriers. The high proviral load in IDH was not associated with age, duration of illness, duration of breast-feeding, or activity status of the skin disease. Therefore, it is likely that patients who have high proviral loads were already infected with a high viral load or are genetically susceptible.

The main finding of the present study was the fact that there was no statistically significant difference between viral replication in IDH and that observed in adulthood HAM/TSP. In addition, the proviral load detected in the IDH patients was much higher than that observed in HTLV-1-infected children with eczema (10). A high proviral load has been demonstrated to represent a risk factor for the development of adult HAM/TSP (13). Thus, a high proviral load in IDH may probably predispose (in addition to other factors) to the development of juvenile HAM/TSP, at least in Bahia, Brazil, where 30% of the IDH patients develop myelopathy.

Acknowledgments

Research supported by Conselho Nacional de Pesquisa (CNPq), Fundação de Amparo à Pesquisa do Estado da Bahia (FAPESB), and NIH/Fogarty International Center grant D43 TW007127.

We acknowledge Dr. Aurélia Porto, Dr. André Muniz and Dr. Carlos Brites (Universidade Federal da Bahia) for medical and laboratory assistance.

References

  • 1.Dourado I, Alcantara LC, Barreto ML, da Gloria TM, Galvao-Castro B. HTLV-I in the general population of Salvador, Brazil: a city with African ethnic and sociodemographic characteristics. J Acquir Immune Defic Syndr. 2003;34:527–531. doi: 10.1097/00126334-200312150-00013. [DOI] [PubMed] [Google Scholar]
  • 2.Oliveira MF, Brites C, Ferraz N, Magalhaes P, Almeida F, Bittencourt AL. Infective dermatitis associated with the human T cell lymphotropic virus type I in Salvador, Bahia, Brazil. Clin Infect Dis. 2005;40:e90–e96. doi: 10.1086/430064. [DOI] [PubMed] [Google Scholar]
  • 3.La Grenade L, Manns A, Fletcher V, Derm D, Carberry C, Hanchard B, et al. Clinical, pathologic, and immunologic features of human T-lymphotrophic virus type I-associated infective dermatitis in children. Arch Dermatol. 1998;134:439–444. doi: 10.1001/archderm.134.4.439. [DOI] [PubMed] [Google Scholar]
  • 4.Primo JR, Brites C, Oliveira MF, Moreno-Carvalho O, Machado M, Bittencourt AL. Infective dermatitis and human T cell lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis in childhood and adolescence. Clin Infect Dis. 2005;41:535–541. doi: 10.1086/432058. [DOI] [PubMed] [Google Scholar]
  • 5.Hanchard B, LaGrenade L, Carberry C, Fletcher V, Williams E, Cranston B, et al. Childhood infective dermatitis evolving into adult T-cell leukaemia after 17 years. Lancet. 1991;338:1593–1594. doi: 10.1016/0140-6736(91)92413-v. [DOI] [PubMed] [Google Scholar]
  • 6.Farre L, de Oliveira MF, Primo J, Vandamme AM, Van Weyenbergh J, Bittencourt AL. Early sequential development of infective dermatitis, human T cell lymphotropic virus type 1-associated myelopathy, and adult T cell leukemia/lymphoma. Clin Infect Dis. 2008;46:440–442. doi: 10.1086/524695. [DOI] [PubMed] [Google Scholar]
  • 7.Maloney EM, Hisada M, Palmer P, Brooks K, Pate E, Wiktor SZ, et al. Human T cell lymphotropic virus type I-associated infective dermatitis in Jamaica: a case report of clinical and biologic correlates. Pediatr Infect Dis J. 2000;19:560–565. doi: 10.1097/00006454-200006000-00014. [DOI] [PubMed] [Google Scholar]
  • 8.Gabet AS, Mortreux F, Talarmin A, Plumelle Y, Leclercq I, Leroy A, et al. High circulating proviral load with oligoclonal expansion of HTLV-1 bearing T cells in HTLV-1 carriers with strongyloidiasis. Oncogene. 2000;19:4954–4960. doi: 10.1038/sj.onc.1203870. [DOI] [PubMed] [Google Scholar]
  • 9.Maloney EM, Nagai M, Hisada M, Soldan SS, Goebel PB, Carrington M, et al. Prediagnostic human T lymphotropic virus type I provirus loads were highest in Jamaican children who developed seborrheic dermatitis and severe anemia. J Infect Dis. 2004;189:41–45. doi: 10.1086/380567. [DOI] [PubMed] [Google Scholar]
  • 10.Maloney EM, Yamano Y, Vanveldhuisen PC, Sawada T, Kim N, Cranston B, et al. Natural history of viral markers in children infected with human T lymphotropic virus type I in Jamaica. J Infect Dis. 2006;194:552–560. doi: 10.1086/506365. [DOI] [PubMed] [Google Scholar]
  • 11.Dehee A, Cesaire R, Desire N, Lezin A, Bourdonne O, Bera O, et al. Quantitation of HTLV-I proviral load by a TaqMan real-time PCR assay. J Virol Methods. 2002;102:37–51. doi: 10.1016/s0166-0934(01)00445-1. [DOI] [PubMed] [Google Scholar]
  • 12.Nagai M, Usuku K, Matsumoto W, Kodama D, Takenouchi N, Moritoyo T, et al. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol. 1998;4:586–593. doi: 10.3109/13550289809114225. [DOI] [PubMed] [Google Scholar]
  • 13.Bangham CR, Hall SE, Jeffery KJ, Vine AM, Witkover A, Nowak MA, et al. Genetic control and dynamics of the cellular immune response to the human T-cell leukaemia virus, HTLV-I. Philos Trans R Soc Lond B Biol Sci. 1999;354:691–700. doi: 10.1098/rstb.1999.0422. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES